Tardive dyskinesia in the treatment of schizophrenia: The findings of the Research on Asian Psychotropic Prescription Pattern (REAP) survey (2001-2009)

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 6, 2011, Pages 382-387

  Xiang, Yu Tao ^a,b   Wang, C Y ^b   Si, T M ^c   Lee, E H M ^a   He, Y L ^d   Ungvari, G S ^e   Chiu, H F K ^a   Yang, S Y ^f   Chong, M Y ^g   Tan, C H ^h   Kua, E H ^h   Fujii, S ⁱ   Sim, K ^j   Yong, K H ^j   Trivedi, J K ^k   Chung, E K ^l   Udomratn, P ^m   Chee, K Y ⁿ   Sartorius, N ^o   Shinfuku, N ^p  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY SIXTH HOSPITAL   (China)

^d SHANGHAI MENTAL HEALTH CENTER   (China)

^e UNIVERSITY OF NOTRE DAME   (Australia)

^f TAIPEI CITY HOSPITAL   (Taiwan)

^g CHANG GUNG UNIVERSITY   (Taiwan)

^h NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

ⁱ Hyogo Institute for Traumatic Stress   (Japan)

^j INSTITUTE OF MENTAL HEALTH   (Singapore)

^k KING GEORGE'S MEDICAL UNIVERSITY   (India)

^l Seoul National University   (South Korea)

^m PRINCE OF SONGKLA UNIVERSITY   (Thailand)

ⁿ HOSPITAL KUALA LUMPUR   (Malaysia)

^o UNIVERSITY OF GENEVA   (Switzerland)

^p SEINAN GAKUIN UNIVERSITY   (Japan)

more..

Author keywords

Ethnicity; Schizophrenia; Tardive dyskinesia

Indexed keywords

CHOLINESTERASE INHIBITOR;

ADULT; AGE; ARTICLE; CLINICAL DECISION MAKING; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNIC DIFFERENCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; SCHIZOPHRENIA; SEX DIFFERENCE; SOCIAL STATUS; TARDIVE DYSKINESIA;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; SCHIZOPHRENIA; TIME FACTORS;

EID: 79959466318     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201505     Document Type: Article

References (43)

1. Yassa R, Jeste DV. Gender differences in tardive dyskinesia: a critical review of the literature. Schizophrenia Bull. 1992; 18: 701-715.
2. Chiu H, Shum P, Lau J, Lam L, Lee S. Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among Chinese psychiatric patients in Hong Kong. Am J Psychiat. 1992; 149: 1081-1085.
3. Ko GN, Zhang LD, Yan WW, Zhang MD, Buchner D, Xia ZY et al. The Shanghai 800: prevalence of tardive dyskinesia in a Chinese psychiatric hospital. Am J Psychiat. 1989; 146: 387-389. (Pubitemid 19078209)
4. Leung SK, Ungvari GS, Ng FS, Cheung HK, Leung T. Tardive dyskinesia in Chinese inpatients with chronic schizophrenia. Prog Neuro-Psychoph. 2003; 27: 1029-1035. (Pubitemid 37141392)
5. Pi EH, Gutierrez MA, Gray GE. Tardive dyskinesia: cross-cultural perspectives. In: Lin KM, Poland RE, Nakasaki G, (eds.). Psychopharmacology and psychobiology of ethnicity. Washington DC: American Psychiatric Press; 1993. p. 153-167.
6. Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon BJ, Tohen M. Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic study. J Clin Psychiat. 2008; 69: 1580-1588.
7. Sundram S, Lambert T, Piskulic D. Acculturation is associated with the prevalence of tardive dyskinesia and akathisia in community-treated patients with schizophrenia. Acta Psychiat Scand. 2008; 117: 474-478. (Pubitemid 351678474)
8. Tenback DE, van Harten PN, van Os J. Non-therapeutic risk factors for onset of tardive dyskinesia in schizophrenia: a meta-analysis. Movement Dis. 2009; 24: 2309-2315.
9. Wszola BA, Newell KM, Sprague RL. Risk factors for tardive dyskinesia in a large population of youths and adults. Exp Clin Psychopharm. 2001; 9: 285-296. (Pubitemid 32762876)
10. Chong MY, Tan CH, Fujii S, Yang SY, Ungvari GS, Si T et al. Antipsychotic drug prescription for schizophrenia in East Asia: rationale for change. Psychiat Clinl Neuros. 2004; 58: 61-67. (Pubitemid 38200373)
11. Shinfuku N, Tan CH. Pharmacotherapy for schizophrenic inpatients in East Asia - changes and challenges. Int Rev Psychiatry. 2008; 20: 460-468.
12. Sim K, Su A, Fujii S, Yang SY, Chong MY, Ungvari GS et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Brit J Clin Pharmacol. 2004; 58: 178-183. (Pubitemid 39043998)
13. APA. Practice Guideline for the Treatment of Patients with Schizophrenia. Washington, DC: American Psychiatric Press; 1997.
14. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharm. 1998; 8: 55-66.
15. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiat. 2003; 64: 663-667. (Pubitemid 36750143)
16. Kasper S, Lowry AJ, Hodge A, Bitter I, Dossenbach M. Tardive Dyskinesia: analysis of outpatients with schizophrenia from Africa and the Middle East, Asia, Central and Eastern Europe, and Latin America. Schizophr Res. 2006; 81: 139-143.
17. Tenback DE, van Harten PN, Slooff CJ, Belger MA, van Os J. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study. J Clin Psychiat. 2005; 66: 1130-1133. (Pubitemid 41442279)
18. Tenback DE, van Harten PN, Slooff CJ, van Os J. Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Am J Psychiat. 2006; 163: 1438-1440.
19. Chong SA, Mahendran R, Machin D, Chua HC, Parker G, Kane J. Tardive dyskinesia among Chinese and Malay patients with schizophrenia. J Clin Psychopharm. 2002; 22: 26-30. (Pubitemid 34101289)
20. Zhang XY, Chen da C, Qi LY, Wang F, Xiu MH, Chen S et al. Gender differences in the prevalence, risk and clinical correlates of tardive dyskinesia in Chinese schizophrenia. Psychopharmacology. 2009; 205: 647-654.
21. Bertilsson L. Metabolism of antidepressant and neuroleptic drugs by cytochrome p450s: clinical and interethnic aspects. Clin Pharmacol Ther. 2007; 82: 606-609. (Pubitemid 47622529)
22. Chong SA. Tardive dyskinesia in CYP2D6 polymorphism in Chinese. Brit J Psychiat. 1997; 171: 586.
23. Garcia-Barcelo MM, Lam LC, Ungvari GS, Lam VK, Tang WK. Dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. J Neural Transm. 2001; 108: 671-677. (Pubitemid 32662411)
24. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiat. 1982; 39: 486-487.
25. Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am J Psychiat. 1999; 156: 309-311. (Pubitemid 29077124)
26. Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH et al. Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res. 2005; 80: 33-43. (Pubitemid 41587461)
27. Waddington JL. Tardive dyskinesia in schizophrenia and other disorders: Associations with ageing, cognitive dysfunction and structural brain pathology in relation to neuroleptic exposure. Hum Psychopharm Clin. 1987; 2: 11-22.
28. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiat Scand. 2000; 401 (Suppl.): 3-38. (Pubitemid 30412890)
29. Tamminga CA. Gender and schizophrenia. J Clin Psychiat. 1997; 58 (Suppl. 15): 33-37. (Pubitemid 28047253)
30. Patterson BD, Swingler D, Willows S. Prevalence of and risk factors for tardive dyskinesia in a Xhosa population in the Eastern Cape of South Africa. Schizophr Res. 2005; 76: 89-97. (Pubitemid 40824564)
31. Liddle PF, Barnes TR, Speller J, Kibel D. Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia. Brit J Psychiat. 1993; 163: 776-780. (Pubitemid 23352971)
32. Perenyi A, Norman T, Burrows GD. Relationship of symptomatology of schizophrenia and tardive dyskinesia. Eur Neuropsychopharm. 1992; 2: 51-55.
33. Yuen O, Caligiuri MP, Williams R, Dickson RA. Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures. Brit J Psychiat. 1996; 168: 702-708.
34. Kane JM. Schizophrenia. N Engl J Med. 1996; 334: 34-41.
35. Saltz BL, Woerner MG, Kane JM, Lieberman JA, Alvir JM, Bergmann KJ et al. Prospective study of tardive dyskinesia incidence in the elderly. JAMA. 1991; 266: 2402-2406.
36. Umbricht D, Kane JM. Medical complications of new antipsychotic drugs. Schizophrenia Bull. 1996; 22: 475-483. (Pubitemid 26295350)
37. Greil W, Haag H, Rossnagl G, Ruther E. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Brit J Psychiat. 1984; 145: 304-310. (Pubitemid 14066482)
38. Ferris C, Dimitrijevic P, Jacobsson L, Paulsson P, Rapp W, Froberg H. Tardive dyskinesia in psychiatric patients treated with neuroleptics. Brit J Psychiat. 1979; 135: 509-514. (Pubitemid 10214524)
39. Kane JM, Smith JM. Tardive dyskinesia: prevalence and risk factors, 1959 to 1979. Arch Gen-Psychiat. 1982; 39: 473-481.
40. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch GenPsychiat. 2007; 64: 1123-1131. (Pubitemid 47529346)
41. Muscettola G, Pampallona S, Barbato G, Casiello M, Bollini P. Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiat Scand. 1993; 87: 29-36. (Pubitemid 23024863)
42. de Jesus Mari J, Lima MS, Costa AN, Alexandrine N, Rodrigues-Filho S, de Oliveira IR et al. The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders. Eur Arch Psy Clin Neurosci. 2004; 254: 356-361. (Pubitemid 40192989)
43. Weiden PJ, Mann JJ, Haas G, Mattson M, Frances A. Clinical nonrecognition of neuroleptic-induced movement disorders: a cautionary study. Am J Psychiat. 1987; 144: 1148-1153. (Pubitemid 17147517)